Nakanishi, Hayato
Teixeira, Andre F.
Matar, Reem H.
Hage, Karl
Acosta, Andres J.
Abu Dayyeh, Barham K.
Pullatt, Rana
Clapp, Benjamin
Ghanem, Omar M. http://orcid.org/0000-0003-2459-2621
Article History
Received: 2 November 2022
Revised: 28 December 2022
Accepted: 30 December 2022
First Online: 7 January 2023
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Informed consent does not apply.
: Andres J. Acosta is a stockholder in Gila Therapeutics, Phenomix Sciences; he served as a consultant for Rhythm Pharmaceuticals, General Mills, Amgen, Bausch Health, RareDiseases, and Nestle Health. Barham K. Abu Dayyeh reports consultant roles with Boston Scientific, Medtronic, USGI, Metamodix, and has had speaking roles with Olympus, Johnson and Johnson (speaker), and Endogastric solutions (speaker). He has grant and research support from Medtronic, Apollo Endosurgery, USGI, Cairn Diagnostics, Aspire, and Spatz medical. Rana Pullatt is a proctor for Intuitive. The remainder of the authors declares no competing interests.